Larimar plans rolling BLA for nomlabofusp in June 2026; Q1 net loss $29.6M

Larimar Therapeutics, Inc.

Net loss Q1 2026 $29.6M ($0.31/sh) vs Q1 2025 $29.3M ($0.46/sh). Cash $200.4M.
Intends to initiate rolling BLA seeking accelerated approval June 2026; CMC module H2 2026.
Topline open-label study data expected Q2 2026; Phase 3 first patient dose mid-2026.
Breakthrough Therapy Designation granted Feb 2026. Skin frataxin as surrogate endpoint supported by published data.
Feb 2026 $115M public offering extended cash runway into Q2 2027.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Larimar Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income net loss for the first quarter of 2026 of $29.6 million, or $0.31 per share of common stock, EPS $0.31 per share of common stock.

Period: first quarter ended March 31, 2026
Net income: net loss for the first quarter of 2026 of $29.6 million, or $0.31 per share of common stock
EPS: $0.31 per share of common stock
Result: reported results

Exact text from the filing

The Company reported a net loss for the first quarter of 2026 of $29.6 million, or $0.31 per share of common stock, compared to a net loss of $29.3 million, or $0.46 per share of common stock, for the first quarter of 2025.

View on SEC.gov

Browse all earnings releases →

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-222746

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.